Stefano Cascinu

Request an appointment

Specialty:

Oncology Gastrointestinal Diseases Gastrointestinal Cancers Pancreatic Cancer Pancreatic Surgery

Profession:

Oncologist

Location:

Department of Clinical Oncology @ Ospedale San Raffaele

Languages:

Request an appointment

Biography

Professor Stefano Cascinu is the Director of the Strategic Research Program in Upper GI Oncology at San Raffaele Hospital in Milan and Full Professor of Medicine at Vita-Salute San Raffaele University.

In 1985, Professor Cascinu graduated from the Faculty of Medicine and Surgery at the University of Ancona; in 1988 he completed a specialization program in oncology at the same university. In 2002 completed another specialization - in Oncological radiotherapy - at the University of Bologna. He also completed an internship at Einstein College in New York, USA.

The main area of Professor Cascinu’s clinical interest is the treatment of tumors of the gastrointestinal tract. In particular, his attention is drawn to the treatment of neoplasms of the esophagus, stomach, colon, pancreas and biliary tract.

Professor Cascinu has made a valuable contribution to the treatment of gastric and pancreatic cancer.

His research activities are focused on the biological characterization and development of innovative treatments for neoplasms of the gastrointestinal tract.

Professor Cascinu is the author and co-author of 525 publications in the scientific journals and books’ chapters. The H index is 56. Professor Cascinu constantly participates in national and international congresses of the field.

Education

University of Ancona
Degree in Medicine and Surgery - 1985

University of Ancona
Specialization in Oncology - 1988

University of Bologna
Specialization in radiation therapy for cancer - 2002

Do you need an appointment?

Request an appointment

Publications

Latest publications

Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?

Int J Cancer. 2019 Mar 1;144

Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S.

GISCAD investigators Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.

Eur J Cancer. 2017 Sep;83:106-115.

Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F

Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain.

Journal of Clinical Oncology 2016; 34: 436–42

Bandieri E, Romero M, Ripamonti CI, et al.

Addressing the challenges of pancreatic cancer: Future directions for improving outcomes.

Pancreatology 2015; 15: 8–12

Hidalgo M, Cascinu S, Kleeff J, et al

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, noninferiority phase 3 study.

The Lancet Oncology 2014; 15:

Price TJ, Peeters M, Kim TW, et al

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Journal of Clinical Oncology 2011; 29: 2011–9

Van Cutsem E, Köhne C-H, Láng I, et al

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer

Journal of Clinical Oncology 2009; 27: 2622–9

Loupakis F, Pollina L, Stasi I, et al.

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer:a randomised, multicentre, phase II trial.

The Lancet Oncology 2008; 9: 39–44

Cascinu S, Berardi R, Labianca R, et al.

Nuclear factorkB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

Journal of Clinical Oncology 2007; 25: 3930–5

Scartozzi M, Bearzi I, Pierantoni C, et al

Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

Journal of Clinical Oncology 2006; 24: 1883–91

Ruzzo A, Graziano F, Kawakami K, et al.

Prognostic role of interleukin-1ß gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.

Journal of Clinical Oncology 2005; 23: 2339–45

Graziano F, Ruzzo A, Santini D, et al

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies.

Journal of Clinical Oncology 2004; 22: 4720–6

Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S.

Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer.

Oncogene 2002; 21: 8192–5

Humar B, Graziano F, Cascinu S, et al.

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial.

Journal of Clinical Oncology 1995; 13: 26–32

Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G.

Recombinant human erythropoietin treatment in cisplatinassociated anemia: A randomized, double-blind trial with placebo.

Journal of Clinical Oncology 1994; 12: 1058–62

Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G.

Do you need an appointment?

Request an appointment